Background and Objectives: ABO-incompatible haematopoietic stem cell transplantation (HSCT) presents a challenge to blood component transfusion. The aim of this study was to investigate the weak blood group A or B antigen expression by donor-derived group O red blood cells (RBC) observed following transfusion or minor ABO-incompatible HSCT. In addition, in vitro experiments were performed to elucidate possible mechanisms underlying this phenomenon.
of platelets, formation of immune complexes, endothelial cell damage and multiple organ dysfunction (Heal et al., 1987 (Heal et al., , 1993 Benjamin & Antin, 1999; Lapierre et al., 2005) . Also, donor-derived ABO antibodies from passenger lymphocytes of minor ABO-incompatible HSC graft origin may induce the destruction of transfused group O RBC, possibly mediated through the adsorption of either soluble A/B antigens, A/B antigen/antibody immune complexes or complement components onto the RBC surface (Gajewski et al., 1992; Tiplady et al., 2001; Worel et al., 2002) .
At the molecular level, the ABO gene encodes two different glycosyltransferases, which add either N-acetylgalactosamine (GalNAc) or galactose (Gal) to the H antigen precursor structure, forming A or B antigens, respectively. In haematopoietic tissue, the FUT1 (or H) gene encodes a 2--fucosyltransferase, which synthesises the H antigen mainly on type 2 oligosaccharide acceptors, linked to proteins (approximately 90%) and lipids (approximately 10%) in the RBC membrane. In epithelial cells, the FUT2 (also known as the secretor) gene governs the synthesis of H antigen, preferentially on type 1 precursor chains. It also determines the presence of type 1 ABH antigens in secretions, found in approximately 80% of people, so-called secretors (Daniels, 2013) (Clausen & Hakomori, 1989; Morgan & Watkins, 2000; Ravn & Dabelsteen, 2000) .
The acquisition in vivo of A/B antigens by group O RBC following transfusion or HSCT has previously been observed using standard serological techniques (Renton & Hancock, 1962; Swanson et al., 1971; Needs et al., 1987; Wichmann et al., 1999) and has been attributed to the adsorption from plasma onto RBC of glycosphingolipids with A/B specificity expressed on type 1 oligosaccharides (Garretta et al., 1974; Tilley et al., 1975; Clausen et al., 1985; Jovall et al., 1987) . In the current study, we used a sensitive flow cytometry assay optimised in our laboratory for the semi-quantification of low levels of A/B antigens (Liu et al., 2007; Hult & Olsson, 2010) to assess the extent of antigen acquisition by donor-derived group O RBC in clinical patient samples following transfusion or HSCT. In vitro experiments that mimic the in vivo situation were performed to address the previously proposed adsorption of A/B antigen-bearing glycosphingolipids onto RBC and to investigate the hypothesised conversion of H substance on the RBC surface by enzymatic action of ABO glycosyltransferases in plasma.
MATERIAL AND METHODS

Patients
As part of the clinical monitoring, patients (n = 11) of different ABO blood groups, transplanted with HSC from ABO-incompatible donors of group O or A, were evaluated by extended blood group analysis. Ethylenediamine tetracetic acid (EDTA)-anticoagulated blood samples drawn for routine blood grouping or pre-transfusion testing were analysed and anonymised data included in the study. In addition to their HSCT, seven patients had received blood transfusions from group O blood donors within the last 3 months prior to testing (range: 3-23). Pre-transplant DNA samples were used to establish the patients' secretor status by FUT2 genotyping and for ABO genotyping of selected patients. At the time of investigation, all patients were complete donor chimeras as assessed by computer records of short tandem repeat-polymerase chain reaction analysis (data not shown).
EDTA samples were also collected from non-transplanted patients (n = 15) of groups A, B or AB who had been transfused with RBC units from group O donors. The number of units received within the last 3 months prior to testing varied considerably (range: 1-36). Again, FUT2 genotyping was performed to establish the patients' secretor status.
Donors
Anonymised blood samples from ABO-typed donors (n = 61) collected in acid-citrate-dextrose (ACD) tubes at routine donation were used for in vitro experiments. No extra samples were taken for this study. Secretor status was determined by Lewis blood group phenotyping. Donors whose secretor status could not be concluded by RBC typing only, i.e. Le(a-b-), were not included. The age of the donor ACD samples varied, but none of the samples used were older than 1 week at the start of each experiment. Donor RBC and/or plasma were used.
Serology
ABO and Lewis phenotyping was performed with established and validated methods used at the Department of Clinical Immunology and Transfusion Medicine in Lund, Sweden.
ABO and FUT2 genotyping
Genomic typing of the ABO and FUT2 loci were performed with established and validated methods used at the Nordic Reference Laboratory for Genomic Blood Group Typing (NRLGBT) in Lund, Sweden. Polymerase chain reaction with allele-specific primers (PCR-ASP) was used (Hosseini-Maaf et al., 2007) .
Flow cytometry
Flow cytometry was performed as previously described (Liu et al., 2007; Hult & Olsson, 2010 
In vitro experiments
Group O RBC were mixed with either plasma or RBC from donors of ABO groups A 1 , A 2 or B, both secretors and non-secretors (Fig. 1) . Group O RBC mixed with autologous group O plasma or RBC were included in each experiment as negative controls. 
Investigating plasma-to-cell transfer of ABO antigens
ACD tubes were centrifuged at 1500 × g for 10 min to separate plasma and RBC. Washed and packed group O RBC were suspended 1 : 5 in group A 1 /B/O plasma in appropriately labelled glass tubes that were sealed and placed in either 4 ∘ C, room temperature (RT), 37 ∘ C or 37 ∘ C with constant mixing for up to 16 days. Papain-treated RBC were used in two experiments. Papain treatment was performed according to standard blood bank practice (Fung et al., 2014) . In preparation for flow cytometric analysis, 25 μL RBC from every tube was transferred to a new glass tube and washed thrice in PBS, and 10 μL packed RBC were re-suspended in 400 μL PBS.
Investigating cell-to-cell transfer of ABO antigens
ACD tubes were centrifuged at 1500 × g for 10 min, and plasma and RBC were separated. RBC were washed thrice in PBS. Packed group O RBC were mixed at a ratio of 1 : 4 with packed A 1 /A 2 /B/O RBC in 1 mL Eppendorf tubes and were sealed and placed in an incubator with constant gentle mixing at 37 ∘ C for up to 4 days.
In one experiment, cell-cell mixes diluted with 200 μL of PBS or A/B plasma to a haematocrit of ∼45%, aiming to create a more in vivo-like environment, were incubated in parallel with the undiluted cell-cell mixes. Cells were prepared for flow cytometric analysis as described above.
Detection of A and B glycosyltransferase activity in plasma
A total of 25 μL of a 10% suspension of washed group O RBC were incubated with 190 μL of plasma from group A 1 /A 2 /B/O, non-secretor individuals at 37 ∘ C for up to 48 h under the following conditions: 0·35 mm UDP-GalNAc (Uridine 5 ′ -diphospho-N-acetylgalactosamine disodium salt, Product# U5252, Sigma-Aldrich, Sweden) or UDP-Gal (Uridine 5 ′ -diphosphogalactose disodium salt, Product# U4500, SigmaAldrich, Sweden) and 10 mm MnCl 2 (BioChemika, product #48975, Sigma-Aldrich, Sweden) in a total volume of 250 μL (adapted from Schenkel-Brunner & Tuppy, 1969) . In one experiment, inactivation of glycosyltransferase activity in plasma was attempted with three different approaches: (i) Heat inactivation using ACD plasma incubated for 10 min at 56 ∘ C, (ii) using plasma from blood drawn in EDTA tubes and (iii) using ACD plasma supplemented with an excess of EDTA. EDTA is a well-known chelating agent, and complex binding of the Mn 2+ ions required for ABO transferase activity was anticipated. Cells were prepared for flow cytometric analysis as described above.
RESULTS
Transplanted patients
A total of 11 patients who had been transplanted with ABO-incompatible HSC were tested. Seven patients were also transfused with group O RBC. Repeat samples were available from four patients. The results are summarised in Table 1. When donor-derived group O RBC were tested with anti-A, an increase in mean fluorescence intensity (MFI) compared to group O RBC controls were observed in all patients but one, who had received multiple blood transfusion on consecutive days just before blood sampling. The A antigen levels ranged from low but well detectable to higher, almost subgroup A x -like profiles. The mean MFI values with anti-A were higher in secretors than in the only group A non-secretor patient available for testing (Fig. 2a,b) . Two patients, who were originally group A secretors and had similar transplant and transfusion histories but very different MFI, were genetically defined as ABO*A2.01/O.01.02 and ABO*A1.01/O.02, respectively (Fig. 2e) .
Two group B secretor patients and one group AB secretor patient showed no detectable B antigen on donor-derived group O RBC (Fig. 2d) , although the group AB patient exhibited a weak A antigen expression (Fig. 2c ).
Non-transplanted but transfused patients
A total of 15 patients, secretors and non-secretors of group A, B or AB transfused with RBC from group O donors, were tested. Repeat samples were available in six patients. The results are summarised in Table 2 . All blood group A patients showed an increase in MFI, greater in group A secretors ( Fig. 2f ) than in group A non-secretors (Fig. 2g) . In transfused group B secretor patients, as opposed to the single group B non-secretor tested, a slight rise in MFI was observed compared to group O RBC controls. A particularly informative flow cytometric pattern was observed in a group A secretor patient (Fig. 2h ). Three distinct cell populations were displayed, with MFI values corresponding to A antigen levels of (i) normal group A RBC, (ii) donor-derived group O RBC circulating in group A secretors and (iii) the group O RBC control. This patient had been transfused with 10 U of group O RBC within the last 3 weeks, including 1 U just prior to blood sampling, indicating that time of circulation for transfused group O RBC correlates with A antigen levels adsorbed. In one group A secretor patient transfused with three group O RBC units in 5 consecutive days, repeat samples were available at 2, 4 and 8 weeks, and a rise in MFI of the donor-derived O RBC over time was observed.
In vitro experiments
Investigating plasma-to-cell transfer of ABO antigens. In an attempt to mimic in vitro the circulating donor-derived group O RBC following transfusion or minor ABO-incompatible HSCT in vivo, normal group O RBC were mixed with secretor or non-secretor plasma from group A 1 and B donors. Group O plasma was used as a negative control.
When tested with anti-A, all group O RBC incubated with group A 1 plasma at 37 ∘ C or RT showed an increase in MFI over time compared to the group O plasma control (Fig. 3a) . A greater increase in MFI, corresponding to a higher level of A antigen, was observed when group O RBC were incubated with group A 1 secretor plasma compared to group A 1 non-secretor plasma. Incubating RBC/plasma mixes with or without constant mixing (at 37 ∘ C) did not influence the increase of MFI, whereas incubation at 4 ∘ C gave no rise in MFI compared to the O plasma control. Group O RBC incubated with group B secretor or non-secretor plasma and tested with anti-B showed no rise in MFI over time compared to the group O plasma control (Fig. 3b) .
Investigating cell-to-cell transfer of ABO antigens
Washed and packed group O RBC, mimicking donor-derived group O RBC, were mixed with washed and packed RBC from group A 1 , A 2 and B secretor and non-secretor donors and incubated at 37 ∘ C with constant mixing. Group O RBC were used as a negative control.
When group O RBC incubated with group A 1 RBC were tested with anti-A, a rise in MFI was observed equivalent to the MFI seen in the naturally occurring ABO subgroup A x . When group O RBC incubated with group A 2 or B RBC were tested with anti-A or anti-B, respectively, the rise in MFI was not as apparent as in group O RBC/A 1 RBC mixes but still clearly detectable.
A difference in MFI between cell-cell mixes, including secretors vs non-secretors, was also clearly shown for group A 1 and B mixes (Fig. 4a,b) . No apparent difference was seen with group A 2 secretors vs non-secretors.
Attempting to mimic a more physiological RBC concentration environment, PBS or group A/B non-secretor plasma was added to the RBC mixes. The rise in MFI was not as dramatic as in the undiluted RBC mixes but still detectable when PBS was added. When non-secretor AB plasma was added to the group O RBC/A 1 RBC mixes, the rise in MFI was very discrete (Fig. 4c) , and with the group O RBC/A 2 or B RBC mixes, a rise in MFI was not detectable. (Figs. 4d-f) . The MFI increased with time, and after 48 h, group O RBC incubated with group A 1 and B plasma expressed A and B antigens at a level almost equivalent to normal group A 2 and B RBC. When group O RBC were incubated with group B plasma, UDP-GalNAc and MnCl 2 , they showed a very slight rise in MFI compared with the O plasma control when tested with anti-A. The low levels of A antigen detected in the group O RBC were consistent with the small amounts of A antigen normally detectable in common group B RBC (Goldstein et al., 1989) . When either of the reagents (donor substrate, MnCl 2 or A/B plasma) was excluded or group O plasma was used instead of group A/B plasma, no change in MFI compared to the group O control RBC was observed. Complete inactivation of the glycosyltransferases was achieved only through the addition of an excess of EDTA to ACD plasma. Inactivated A 1 plasma was incubated with group O RBC, UDP-GalNAc and MnCl 2 , and no A antigens could be detected with anti-A.
DISCUSSION
In this study, we demonstrate and semi-quantify the in vivo conversion of donor-derived blood group O RBC to ABO subgroup-like RBC following transfusion to ABO non-identical recipients or after minor ABO-incompatible HSCT. Utilising a sensitive flow cytometry protocol, donor group O RBC were found to express variable levels of acquired antigen, ranging from very small amounts in non-secretor individuals to subgroup A x -like profiles in group A 1 secretors. Our findings support the major role of A/B antigen adsorption from secretor plasma but also indicate that secretor status is not an absolute prerequisite for the in vivo conversion of group O RBC.
Detectable levels of antigen adsorbed from secretor plasma into group O RBC may increase over time as demonstrated in the in vitro experiments (Fig. 3a) and illustrated by the characteristic (Fig. 2f) . Also, the time course of antigen adsorption into RBC may be influenced by inhibiting factors in plasma (Tilley et al., 1975) , suggesting competition by plasma lipoproteins for lipid uptake that may have influenced the flow cytometric pattern observed in Fig. 4c .
The marked difference in detectable levels of adsorbed antigen between secretor individuals of different ABO blood groups reflects a variable amount of soluble antigen available in plasma, governed by the complex interaction between the ABO and FUT1 gene, the secretor gene (FUT2) and the Lewis gene (FUT3), and is influenced by allelic variants at these loci. The enzymes encoded by ABO and FUT3 compete for the common type 1H acceptor substrate to produce A/B antigens or difucosylated Le b antigen (Watkins et al., 1988; Henry et al., 1995) . The enzyme produced by the A 1 allele of the ABO locus is more efficient than its A 2 allelic variant in competing with the Lewis enzyme for the type 1H acceptor substrate. Accordingly, among group A secretors of the Le(a−b+) phenotype, levels of soluble A or ALe b antigen are higher in A 1 than A 2 individuals (Holburn & Masters, 1974; Tilley et al., 1975; Achermann et al., 2005) . In two secretor patients, genetically defined as ABO*A1.01/O.02 and ABO*A2.01/O.01.02, respectively (Fig. 2e) , we found a clear difference in A antigen levels in donor-derived group O RBC, corresponding to the quantitative difference in A 1 -and A 2 -glycosyltransferase activity when it comes to synthesis of A type 1 (Schachter & Michaels, 1971; Schenkel-Brunner & Tuppy, 1973) . A possible effect of secretor gene zygosity was suggested by the finding in our study that patients who were typed homozygous for c.428G in their FUT2 genes (i.e. homozygous for active secretor alleles, previously referred to as Se) expressed comparatively high levels of original blood group A/B antigens on donor-derived group O RBC. In another study, however, levels of soluble ABO blood group substance in plasma were not influenced by the homozygous expression of the A 1 , A 2 or Se alleles, respectively (Achermann et al., 2005) .
In non-secretor plasma, A/B antigens are found, albeit in small quantities, on type 2 carbohydrate chains linked to glycoproteins and glycosphingolipids and are presumed to emanate from endothelial or haematopoietic cells (Hostrup, 1962; Holburn & Masters, 1974; Tilley et al., 1975; Le Pendu et al., 1982) . Lactosylceramide, which is the major glycosphingolipid precursor of RBC (Clausen & Hakomori, 1989) , is also expressed in endothelial cells. In plasma, glycosphingolipids are associated with lipoproteins and may, thus, be exchanged between cells and lipoproteins, or vice versa, via shedding and/or receptor-mediated endocytosis (Chatterjee, 1998) . In the recipient of a minor ABO-incompatible HSCT (group O donor to group A recipient, Fig. 2b ), the endothelium is, thus, a plausible source of type 2 A antigen available for transfer to transfused group O RBC. In a transfused group A, non-secretor patient (Fig. 2g) , the haematopoietic tissue may contribute to the total amount of lipid-linked type 2 A antigen available for uptake. A possible mechanism for direct membrane glycolipid exchange between adjacent RBC was also suggested by the in vitro experiments (Fig. 4a-c) , most prominent when RBC were close to each other. Among the plasma glycoproteins known to carry A/B antigens on N-linked oligosaccharide chains, endothelium-derived vWF and a minor portion (10%) of 2 -macroglobulin (Matsui et al., 1993 (Matsui et al., , 1999 circulate in plasma independent of secretor status. Available data, however, suggest that these glycoproteins are not of significant importance to in vivo RBC A/B antigen expression (Kirschkamp et al., 2008; Santizo et al., 2009 ).
The possible mechanism of H substance conversion on the surface of donor-derived group O RBC, by enzymatic action of GTA/GTB in non-secretor plasma, was hypothesised and successfully demonstrated in vitro by adding an excess of the appropriate donor sugar substrate. The A/B-enzymes are present in plasma irrespective of secretor status, with only a minor part originating from haematopoietic tissue (Schachter & Michaels, 1971; Yoshida et al., 1980) , and are generally considered incapable of enzymatic activity on the RBC surface due to insufficient extracellular concentrations of donor sugar nucleotides (Varki et al., 1999) . Also, in the recipient of a minor ABO-incompatible HSCT, inhibiting antibodies directed against endogenous GTA/GTB may completely abolish enzymatic activity in plasma (Barbolla et al., 1988) . However, recent reports have shown evidence for extrinsic glycosylation driven by circulating extracellular glycosyltransferases where the donor sugar substrates are provided by activated platelets (Lee et al., 2014; Lee-Sundlov et al., 2017) .
The difficulties in this study to detect adsorption of B antigen from secretor plasma by donor group O RBC following transplantation (Table 1 , Fig. 2d ) or transfusion (Table 2) , as well as in the in vitro experiments (Fig. 3b) , may either suggest that the GTB is a poorer competitor to the Lewis enzyme for H type 1 substrate in secretions than GTA or that the BLe b antigen is preferentially formed but not detected. Notably, a reduced level of A antigen in donor group O RBC was observed in group A 1 B secretors compared to group A 1 secretors (Tables 1 and 2) , indicating GTB activity resulting in the conversion of H type 1 antigen. The monoclonal antibodies used in this study, anti-A clone ES-15 and anti-B clone 9621A8, were specifically selected for their high sensitivity and ability to detect native ABO subgroups (Hult & Olsson, 2010) and remnant A/B antigens after exoglycosidase treatment (Liu et al., 2007) using flow cytometry. However, in more recent experiments, using clone ES-15 and clone 9621A8 in flow cytometry evaluation of RBC modified with synthetic glycolipid A/B constructs (KODE Technology, KODE Biotech Limited, Auckland, New Zealand), we found that a transformation with five times more B construct than A construct was required to create RBC with equivalent serological and flow cytometric features (Hult et al., 2012) . This phenomenon has been shown to be consistent when either monoclonal or human polyclonal antibodies are tested against both natural and synthetic B antigen and is believed to be due to the structure of the B antigen, which has an inherently lower affinity for a specific antibody, in contrast to the A antigen, which has the N-acetyl protrusion on its terminal sugar. Notwithstanding this, in contrast to the scarce amount of B antigen found to be adsorbed from secretor plasma, the co-incubation of group O and B RBC in the absence of plasma induced readily detectable levels of B antigen in donor group O RBC (Fig. 4b) , suggesting a transfer of B type 2 glycolipids. Notably, this may point to a preference of the anti-B clone 9621A8 for type 2-based B antigen, although the degree of antibody specificity for type 1 vs type 2 oligosaccharides was not investigated in this study. However, the antibody is known to react in enzyme-linked immunosorbent assay (ELISA) with synthetically produced group B oligosaccharides of both type 1 and 2, while BLe b structures were apparently not tested (H. Dekneudt, 2014, personal communication from the manufacturer of the reagent). It is possible that some of the antigen adsorbed into donor cells is indeed of BLe b type, which may explain why the anti-B used does not react readily.
The transient course of donor-derived A/B antibody titres and the apparent escape of endothelial cells from GvHD in minor ABO-incompatible HSCT may be attributed to antibody adsorption, induction of donor lymphocyte tolerance or endothelial cell accommodation (Takahashi, 2005; Stussi et al., 2006) . In contrast, repeat transfusion of donor ABO-type plasma and platelet components may cause immune complex formation, multi-organ dysfunction and impaired survival (Benjamin & Antin, 1999; Heal et al., 2005) . In this setting, circulating donor-derived RBC have an important role in CR1 receptor-mediated clearance of immune complexes (Reinagel et al., 1997) but are, as shown here, also potential targets for direct ABO antibody binding and possibly haemolysis.
In this study, we demonstrate and characterise the in vivo conversion of donor-derived group O RBC to ABO subgroup-like RBC following transfusion or HSCT, utilising a sensitive flow cytometer assay that enables the distinction between HSC donor-derived RBC, expressing low levels of acquired A/B antigen, and reappearing RBC of recipient origin, which may herald relapse or HSC graft rejection (David et al., 1999) . Our findings confirm the major role of A/B antigen adsorption from secretor plasma but also indicate an additional, secretor-independent mechanism for A/B antigen acquisition. In a clinical context, this study provides additional support for the proposed selection of plasma components compatible with both donor and recipient ABO blood group (Heal et al., 2005; O'Donghaile et al., 2012) , these recommendations should also apply after the recipient is considered to have complete HSC engraftment. It can be noted that certain sources still recommend blood components of the donor's ABO group once a routine grouping shows that the cells appear to type as the donor (Fung et al., 2014 ), but our study shows that a highly sensitive flow cytometric analysis is valuable for establishing the recipient's true blood group status.
